Under the agreement, BioLife Solutions shareholders will receive a combination of cash and stock for each share they own. The terms are $11.25 in cash and 0.1442 of a Repligen share, valuing each BioLife Solutions share at approximately $31.00. This strategic move is designed to strengthen Repligen's position in the cell therapy market. On the day of the announcement, BioLife Solutions stock price increased by 6.71% to $31.15, reaching a new 52-week high. This price aligns closely with the acquisition value ...